Biomarker analysis of KN-119 of pembro vs chemo in pretreated mTNBC out in NPJ Breast. Pembro improved OS in pts with TILs ≥5%, no benefit if TILs<5%. Still waiting for the TILs analysis of KN-522, which we hope could refine the use of neoadjuvant pembro. nature.com/articles/s4152…

🚨 Beyond the Hype: Alexis LeVee, MD UCLA Health unpacks 2025 TNBC trials at MOASC / ANCO ✅BELLINI’s 47% pCR chemo-free who benefits? ✅ASCENT-04’s 11.2 mo PFS: Real-world hurdles? 👉 oncologytube.com/breast-cancer-… Iago Ivanovitch 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Abigail Johnston MedxBd

ADCs are revolutionizing breast cancer care. The phase 3 TROPION-Breast02 trial shows improved PFS and OS with Dato-DXd in 1L PD-L1-negative mTNBC. Now we have 2 ADCs in 1L mTNBC, with ASCENT-03 (SG) results expected at #ESMO25. astrazeneca.com/media-centre/p…

So enjoyed the opportunity to talk to Matteo Lambertini, MD PhD about his recent Journal of Clinical Oncology publication related to #BRCA awareness & impact on outcome in young pts with #breastcancer. A brilliant piece that banded together data from 4,752 pts across 78 centers. We also touched on his many

1/ 🚨Hot off the press ✨- Our new article evaluates the efficacy and safety of ADCs + IO in advanced urothelial carcinoma (aUC) 🩺 We conducted a systematic review & meta-analysis of 645 patients across 5 trials: • EV (anti-nectin-4) • SG (anti-TROP2) • DV (anti-HER2)

It’s official: ASCENT-03 and TROPION-Breast02 will be both presented at #ESMO25. Two positive trials, taking Trop2 ADCs to the 1L and improving outcomes for one of the greatest unmet needs in breast oncology — metastatic TNBC. Discussion by Ana Garrido-Castro Dana-Farber’s Breast Oncology Center.

Denosumab increased the rate of severe #irAE in female patients with #breastcancer treated with #ICI Susan Bates Giuseppe Banna pas_rescigno doi.org/10.1093/oncolo…

Another positive trial in 1L HER2+ MBC! HER2CLIMB-05 just reported that adding the oral TKI tucatinib improved PFS in the maintenance setting (with HP) in 1L HER2+ breast cancer. Results to be presented at #SABCS25. pfizer.com/news/press-rel…

#ESMO25 ESMO - Eur. Oncology Low-Dose Pembro in neoadj setting TNBC: - 157 pts randomized to NACT± LDPm. - pCR: 53.8% vs 40.5% (Δ +13.3%; P=0.047) Grade ≥3 AEs: 50% vs 59.5%; 1 treatment-related death > non-inferiority trial needed in this setting? OncoAlert

#ESMO25 - Patients with metastatic breast cancer who had received ≥ 2 years of bone modifying agents🦴were randomized to continue standard dosing (Q4W) or de-escalate to Q24W De-escalation preserved physical function without increasing skeletal events OncoAlert

Impressive results from DB-11, with improvement in pCR rate (67% vs 56%), positive EFS trend & more favorable safety with T-DXd-THP vs ddAC-THP in high risk HER2+ eBC. Benefit mostly seen in N+ patients (90% of the pts). New neoadjuvant treatment option! #ESMO25 #ESMOAmbassadors

Ok, next #DB05 14 cycles of T-DXd vs. T-DM1 as salvage to non-PCR to neoadj therapy (ala KAThERINE design) 📍Notably 30 pts recurred while on T-DM1, only 2 w/ T-DXd Node + 80% (KATHERINE was ~ 55%) 💪🏼👏 iDFS 8.7% better at 3 yrs (83.7 vs. 92.4%) #ESMO25 #ESMOAmbassadors

Very interesting preliminary data to support the use of oral #SERD (in this case #giredestrant) without ovarian function suppression in premenopausal women with HR+/HER2- early #BreastCancer OncoAlert ESMO - Eur. Oncology #ESMO25 Ann Partridge MD, MPH

🦴🧬 Denosumab + Pembrolizumab in Breast Cancer? A Synergistic Story with a Price! 👩‍🦰 425 female pts with breast cancer on pembrolizumab were analyzed: 🔹 Denosumab (n=55) 🔹 Zoledronic acid (n=31) 🔹 No BMA (n=339) 🧩 Severe irAE (Grade ≥3) •Denosumab: 21.8% •Zoledronic

6 wks to go! Excited to discuss how the data from #SABCS25 will change/reinforce our practice at the Advancements in Oncology! In Person, 📆 Date: Dec 10, 2025 ⏰ Time: 7-9PM ✅ Register here: bit.ly/aiosabcs25 Her2: Susan dent & Stephanie Graff, MD, FACP, FASCO TNBC: Erika Hamilton, MD, FASCO

Exciting news that an oral SERD may change the standard of care for many patients with early HR+ breast cancer, with a significant IDFS benefit and a positive trend (data immature) for OS compared to SOC ET